Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;21(12):2173-2179.
doi: 10.1016/j.bbmt.2015.08.022. Epub 2015 Aug 29.

In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children

Doris M Ponce  1 , Mary Eapen  2 , Rodney Sparapani  3 , Tracey A O'Brien  4 , Ka Wah Chan  5 , Junfang Chen  6 , John Craddock  7 , Kirk R Schultz  8 , John E Wagner  9 , Miguel-Angel Perales  1 , Juliet N Barker  1
Affiliations

In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children

Doris M Ponce et al. Biol Blood Marrow Transplant. 2015 Dec.

Abstract

The inclusion of antithymocyte globulin (ATG) in cord blood transplantation is controversial. We evaluated outcomes according to ATG inclusion in 297 children and adolescents with acute lymphoblastic leukemia (ALL) who received myeloablative total body irradiation-based conditioning and either single-unit (74%) or double-unit (26%) grafts. Ninety-two patients (31%) received ATG and 205 (69%) did not. ATG recipients were more likely to be cytomegalovirus seronegative. The incidences of day 100 grades II to IV acute graft-versus-host disease (GVHD; 30% versus 54%, P = .0002) and chronic GVHD (22% versus 43%, P = .0008) were lower with ATG compared with non-ATG regimens. However, day 100 grades III to IV acute GVHD was comparable (11% versus 17%, P = .15). The 3-year incidences of transplant-related mortality (16% versus 17%, P = .98), relapse (17% versus 27%, P = .12), and leukemia-free survival (66% versus 55%, P = .23) in ATG and non-ATG recipients were similar. There were no differences in viral reactivation between treatment groups (60% versus 58%, P = .83). Therefore, the data suggest that incorporation of ATG with myeloablative conditioning regimens may be useful in reducing the risk of acute and chronic GVHD without any deleterious effect on transplant-related mortality, relapse, or leukemia-free survival in children and adolescents with ALL.

Keywords: Acute lymphoblastic leukemia; In vivo T cell depletion; Myeloablative conditioning.

PubMed Disclaimer

Figures

Figure 1A
Figure 1A
Cumulative incidence of grade II-IV acute graft-versus-host disease
Figure 1B
Figure 1B
Cumulative incidence of grade III-IV acute graft-versus-host disease
Figure 2
Figure 2
Cumulative incidence of chronic graft-versus-host disease
Figure 3
Figure 3
Probability of leukemia-free survival
See this image and copyright information in PMC

References

    1. Haidinger M, Geyeregger R, Poglitsch M, et al. Antithymocyte globulin impairs T-cell/antigen-presenting cell interaction: disruption of immunological synapse and conjugate formation. Transplantation. 2007;84(1):117–121. - PubMed
    1. Monti P, Allavena P, Di Carlo V, Piemonti L. Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. Int Immunopharmacol. 2003;3(2):189–196. - PubMed
    1. Gillet-Hladky S, de Carvalho CM, Bernaud J, Bendahou C, Bloy C, Rigal D. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation. 2006;82(7):965–974. - PubMed
    1. Fang L, Fehse B, Engel M, Zander A, Kroger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation. 2005;79(3):369–371. - PubMed
    1. Na IK, Wittenbecher F, Dziubianau M, et al. Rabbit antithymocyte globulin (Thymoglobulin(R)) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients. Haematologica. 2013;98(1):23–30. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources